This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van Vlerken, L. E. Articles by Amiji, M. M. Search for Related Content PubMed Articles by van Vlerken, L. E. Articles by Amiji, M. M.

Modulation of Intracellular Ceramide Using Polymeric Nanoparticles to Overcome Multidrug Resistance in Cancer

¹ Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University and ² Department of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts

Requests for reprints: Mansoor M. Amiji, 110 Mugar Life Sciences Building, 360 Huntington Avenue, Boston, MA 02115. Phone: 617-373-3137; Fax: 617-373-8886; E-mail: m.amiji{at}neu.edu.

Although multidrug resistance (MDR) is known to develop through a variety of molecular mechanisms within the tumor cell, many tend to converge toward the alteration of apoptotic signaling. The enzyme glucosylceramide synthase (GCS), responsible for bioactivation of the proapoptotic mediator ceramide to a nonfunctional moiety glucosylceramide, is overexpressed in many MDR tumor types and has been implicated in cell survival in the presence of chemotherapy. The purpose of this study was to investigate the therapeutic strategy of coadministering ceramide with paclitaxel, a commonly used chemotherapeutic agent, in an attempt to restore apoptotic signaling and overcome MDR in the human ovarian cancer cell line SKOV3. Poly(ethylene oxide)-modified poly(epsilon-caprolactone) (PEO-PCL) nanoparticles were used to encapsulate and deliver the therapeutic agents for enhanced efficacy. Results show that indeed the cotherapy eradicates the complete population of MDR cancer cells when they are treated at their IC₅₀ dose of paclitaxel. More interestingly, when the cotherapy was combined with the properties of nanoparticle drug delivery, the MDR cells can be resensitized to a dose of paclitaxel near the IC₅₀ of non-MDR (drug sensitive) cells, indicating a 100-fold increase in chemosensitization via this approach. Molecular analysis of activity verified the hypothesis that the efficacy of this therapeutic approach is indeed due to a restoration in apoptotic signaling, although the beneficial properties of PEO-PCL nanoparticle delivery seemed to enhance the therapeutic success even further, showing the promising potential for the clinical use of this therapeutic strategy to overcome MDR. [Cancer Res 2007;67(10):4843–50]

This article has been cited by other articles:

				D. Zheng, X. Li, H. Xu, X. Lu, Y. Hu, and W. Fan Study on docetaxel-loaded nanoparticles with high antitumor efficacy against malignant melanoma Acta Biochim Biophys Sin, July 1, 2009; 41(7): 578 - 587. [Abstract] [Full Text] [PDF]

				Z. Duan, E. J. Weinstein, D. Ji, R. Y. Ames, E. Choy, H. Mankin, and F. J. Hornicek Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer Mol. Cancer Ther., August 1, 2008; 7(8): 2377 - 2385. [Abstract] [Full Text] [PDF]

				H. Devalapally, Z. Duan, M. V. Seiden, and M. M. Amiji Modulation of Drug Resistance in Ovarian Adenocarcinoma by Enhancing Intracellular Ceramide Using Tamoxifen-Loaded Biodegradable Polymeric Nanoparticles Clin. Cancer Res., May 15, 2008; 14(10): 3193 - 3203. [Abstract] [Full Text] [PDF]